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ABSTRACT
Bladder cancer (BC) is the 9th most common cancer worldwide, and the 6th most 
common cancer in men. Its development is linked to chronic inflammation, genetic 
susceptibility, smoking, occupational exposures and environmental pollutants. Aim of 
this work was to identify a sub-network of genes/proteins modulated by environmental 
or arsenic exposure in BC by computational network approaches. Our studies evidenced 
the presence of HUB nodes both in “BC and environment” and “BC and arsenicals” 
networks. These HUB nodes resulted to be correlated to circadian genes and targeted 
by some miRNAs already reported as involved in BC, thus suggesting how they play an 
important role in BC development due to environmental or arsenic exposure. Through 
data-mining analysis related to putative effect of the identified HUB nodes on survival 
we identified genes/proteins and their mutations on which it will be useful to focus 
further experimental studies related to the evaluation of their expression in biological 
matrices and to their utility as biomarkers of BC development.
INTRODUCTION
Bladder cancer (BC) is the 9th most common 
cancer worldwide, and the 4th most common cancer in 
more developed world [1–3]. In the last years, BC risk 
has been linked to the smoking, to the occupational 
exposures [4], to the use of drugs like cyclophosphamide 
or chlornaphazine [5], to the environmental pollutants 
and the arsenicals [6, 7], and to the chronic inflammation 
with the related up-regulation of some pro-inflammatory 
proteins like interleukin (IL)-6, tumor necrosis factor 
(TNF) and C-reactive protein (CRP) [8]. Moreover, a 
strong correlation between altered expression of various 
clock genes (PER1 and PER2) and common tumor 
markers (TP53, PTEN and PAI-1) evidenced that a 
disturbed function in the cellular clock system can clearly 
represent an another mechanism of BC progression [9].
In particular, many studies reported experimental 
evidences about the role of the environmental chemicals in 
BC carcinogenesis. In fact, the increased COX-2 expression 
and the activation of the mitogen activated protein kinase 
pathway in BC cells exposed to monomethylarsonous 
acid, a metabolite of inorganic arsenic, resulted a strong 
mechanism for BC carcinogenesis [10]. Moreover, it has 
been demonstrated in mice and rats the BC carcinogenicity 
of both 3-amino-1-methyl-5H-pyrido[4,3-b]indole, that is 
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formed in cooked meat and fish [11], and pellets containing 
crude tryptophan pyrolysate and its derivates [12]. On 
the other hand, the exposure to high concentrations of 
diesel engine emissions, belonging to the sub-category 
of pollutants named as vehicle emissions, as well as 
insecticides, fungicides and pesticides resulted to contribute 
to carcinogenesis [13–15].
Our research group works in Campania, a region of 
Italy, in which BC incidence is very high with 75.3 cases 
per 100000 inhabitants, in comparison to only 19 cases 
per 100000 inhabitants in Europe in 2012 [3]. In the last 
decades, large areas of the Naples and Caserta provinces 
have been extensively contaminated by the widespread 
burial and open air dumping and incineration of industrial 
toxic waste [16]. Recently, the serum levels of arsenic 
measured in living subjects of five municipalities in the 
Naples province resulted to be higher than expected 
compared to national average [16].
Since the etiology of BC development is multi-
factorial, only its early detection can reduce mortality. 
Hence, the development of new non-invasive biomarkers 
would benefit patients. Some reviews in literature report 
a summary of studies conducted through different omics 
approaches aimed to evaluate the transcriptome, the 
miRNome, the metabolome and the long non coding 
RNAs profiling involved in BC [16–21].
However, any detailed information is reported 
until now about what genes/proteins modulated by 
environmental exposure or by only arsenicals are involved 
in BC development or progression, how they are correlated, 
and what metabolic pathways are affected. Therefore, 
our aim was to select the genes/proteins modulated by 
environmental exposure (comprising arsenicals, pollutants, 
smoking, insecticides, fungicides and pesticides) or by only 
arsenicals in BC starting from Comparative Toxicogenomics 
Database (CTD), and to correlate them by a computational 
network approach. Through this method, we identified: i) 
the specific HUB nodes, that are nodes with a large degree 
and have connections with many other nodes, ii) the HUB-
HUB interaction sub-network between HUB nodes that can 
be considered as specific of the correlation between BC and 
environment, and, hence, of the BC development due to 
environmental exposure, iii) the correlations between HUB 
nodes with circadian genes and miRNAs, iv) effect of HUB 
nodes on survival outcome of BC patients and their mutational 
status in this cancer. Therefore, further experimental studies 
could be focused on these HUB nodes to verify their utility 
as new diagnostic and/or prognostic biomarkers as well as 
potential targets for chemoprevention approach.
RESULTS AND DISCUSSION
Selection of environmental chemicals implicated 
in BC and the related modulated proteins
To create an interaction network between proteins 
modulated by environmental exposure in BC, we followed 
a protocol reported in Figure 1. Firstly we extracted the 
list of environmental chemicals implicated in BC and of 
the related proteins modulated by them using Comparative 
Toxicogenomics Database (CTD) [22]. The selected 
chemicals were grouped in the four following categories: 
arsenicals, smoking, pollutants and others, comprising 
insecticides, fungicides and pesticides, by considering 
also the studies already reported in literature [10–15] 
(Supplementary Table 1). About the identified proteins, we 
found 51 proteins modulated by arsenicals, 40 by smoking 
molecules, 94 by pollutants and 73 by other chemicals 
(Figure 2 and Supplementary Table 2). A molecular 
pathway analysis was conducted on all the proteins 
belonging to these four categories (Supplementary Table 
3), and the molecular pathways, that were common or 
specific between the four categories, were extracted 
(Supplementary Table 4). In details, we can evidence 
the presence of some common pathways, that are strictly 
correlated to the cancer, among which: i) TNF and NOD-
like receptor signaling pathway were common between 
arsenicals and smoking sub-groups; ii) Rap1, estrogen, 
prolactin, TGF-beta and VEGF signaling pathways were 
common between arsenicals, pollutants and “others” 
sub-groups; iii) hematopoietic cell lineage and Cytokine-
cytokine receptor interaction molecular pathway were 
common between smoking and “others” sub-groups; 
iv) chemical carcinogenesis was common between 
smoking, pollutants and “others” sub-groups, and v) drug 
metabolism - cytochrome P450 was common between 
smoking and pollutants sub-groups. However, it is 
important to underline that, although different categories 
of chemicals are able to regulate similar pathways even if 
through different proteins along the same pathway, they 
can generate distinct molecular/cellular outputs.
Moreover, we evaluated also the pathways that are 
specific for each chemical category, and found for example: 
i) regulation of actin cytoskeleton, Wnt and Chemokine 
signaling pathway for arsenicals; ii) drug metabolism - other 
enzymes and metabolism of xenobiotics by cytochrome 
P450 for pollutants; iii) AK-STAT signaling pathway for 
“others” sub-group. Any specific molecular pathway for 
smoking was evidenced (Supplementary Table 4).
Moreover, a detailed analysis of the proteins 
modulated by only one chemical sub-category showed 
that FBXW8 was modulated only by arsenicals, ANXA2R 
only by smoking chemicals, and nineteen proteins 
(ASXL2, RALGPS1, STAG2, SMC1B, SMC1A, TYMP, 
SLC12A7, ARID1A, TACC3, APOBEC3B, MLL2, 
LOXL4, CALMHM1, NRSN1, EOMES, KMT2A, CHD6, 
VWA3A, KDM6A) only by pollutants (Figure 2 and 
Supplementary Table 2).
In details, FBXW8 is a member of the F-box 
protein family that acts in phosphorylation-dependent 
ubiquitination whereas ANXA2R may act as a receptor for 
annexin A2 that plays a role in the regulation of cellular 
growth and in signal transduction pathways. Regarding 
the nineteen proteins modulated by the pollutants, only 
Oncotarget3www.impactjournals.com/oncotarget
Figure 1: Flow-chart of the protocol used to identify and to analyse HUB nodes in “BC and environment” network.
Figure 2: Venn diagram evidences the proteins that are modulated by four chemical sub-groups (arsenicals, smoking, 
pollutants and others). In this way it is possible to see the number of proteins modulated by only a sub-group or from two, three or 
four groups.
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STAG2, SMC1A and SMC1B resulted to be involved in 
the enriched molecular pathway named cell cycle.
However, through the Venn diagram analysis, we 
verified also the presence of twenty-two proteins that are 
modulated in BC by all four chemical sub-groups: CDH1, 
KRAS, IGFBP3, GSTM1, IGF1, TP53, IGFBP5, GSTP1, 
PTGS2, TNF, GPX1, CXCL8, CDKN2A, SOD2, EGFR, 
NQO1, MYC, CDKN1A, MT2A, BIRC3, FAS and ESR1 
(Figure 2). These proteins are involved in the following 
molecular pathways: p53 signaling, MAPK signaling, 
Apoptosis, ErbB signaling, Cell cycle and Glutathione 
metabolism (Supplementary Table 5).
Since our principal aim was to identify a sub-network 
of genes/proteins modulated by environmental exposure 
in BC, we decided to focus our attention on the proteins 
modulated by all four chemical sub-groups and to create the 
general network of interaction between BC and environment.
Identification and analysis of HUB nodes in “BC 
and environment” network
On the basis of the human molecular interactome 
and of the list of the twenty-two proteins, reported above, 
the “BC and environment” interaction network was 
created and analyzed. In detail, we mapped our twenty-two 
proteins on the human molecular interactome (INTACT) 
[23], extracted their related interaction network (named 
as “BC and environment”) composed by 1839 nodes and 
2376 interactions and analyzed it by the related topological 
properties, reported in the Methods section, in order to 
understand the position and the role of these proteins 
present as nodes in the network (Supplementary Figure 1) 
[24]. In this way, we selected HUB nodes, which are the 
nodes with the strongest coordination role by considering 
a consensus of four out of six measures of centrality and 
topology (see Methods section). The following fifteen 
HUB nodes were identified: KRAS, IGFBP3, GSTM1, 
TP53, GSTP1, TNF, CXCL8, CDKN2A, SOD2, EGFR, 
NQO1, MYC, CDKN1A, FAS, and ESR1. They resulted 
to be up-regulated in BC by microarray studies with 
the exception of GSTP1 and ESR1 [25–31], and be 
involved in specific molecular functions and pathways 
(Supplementary Tables 5 and 6). We can speculate that 
the most part of identified HUB nodes is involved in 
molecular pathways correlated to cancer development 
and do not seem specific for BC. However, among these 
nodes, it is important to evidence the presence of GSTP1 
and ESR1, about which few information is reported in 
BC. In general, GSTP1 catalyzes the conjugation of many 
hydrophobic and electrophilic compounds with reduced 
glutathione. It is reported that its polymorphisms are 
among the genetic determinants related to lead-induced 
inflammatory response and may modulate the response 
to epithelial oxidative changes caused by air pollutant 
exposure in lung [32]. Hence, it could be interesting and 
useful to study how GSTP1 is involved in BC development 
after environmental chemical exposure. In regard to ESR1, 
it is an estrogen receptor involved in sexual development 
and reproductive function. Considering that some 
environmental chemicals such as endosulfan and dieldrin 
are endocrine disruptors that can cause negative effects on 
the endocrine functions by miming the action of steroid 
hormones due to their structure similar to these last ones, 
we can think in future to investigate in more detail how 
ESR1 can be affected by these chemicals and through 
what mechanisms it can be involved in BC carcinogenesis.
About the obtained network a detailed analysis of 
the statistical centrality and topological measures has 
permitted to evidence its effectiveness and its robustness. 
In fact, it is important to underline that our network has 
a centralization value of 0.423, a network density of 
0.001, a heterogeneity value of 9.899 and characteristic 
path length of 3.330. Overall these data evidenced that: 
i) the network effectiveness is elevated with nodes that 
are highly correlated between them; ii) the network is of 
small world type characterized by short path lengths [33]. 
Moreover, the plot of the node degree distribution showed 
a decreasing trend demonstrating that our network had 
scale free property indicating that it follows the role that 
“riches get richer” (Supplementary Figure 2) [34–37]. On 
the other hand the clustering coefficient graph showed a 
decreasing trend highlighting the tendency of our network 
to contain HUB nodes [37]. However, considering that the 
betweenness centrality is a measure to obtain inferences 
on the importance of inter-connected proteins on the 
basis of load placed on the given node in the network, 
the increasing trend of the betweenness centrality in 
our network demonstrated that the following five HUB 
nodes had the maximum load: i) TP53 (tumor protein 
p53), a DNA binding tumor suppressor protein, ii) MYC 
(c-MYC), a multifunctional and nuclear phosphoprotein 
that plays a role in cell cycle progression, apoptosis and 
cellular transformation, iii) EGFR (Epidermal Growth 
Factor Receptor), a cell surface receptor, iv) ESR1 
(estrogen receptor), a nuclear hormone receptor and v) 
CDKN1A (Cyclin Dependent Kinase Inhibitor 1A) which 
functions as a regulator of cell cycle progression at G1.
Then, to study if in the network there were clusters 
and/or modules characterized by groups of nodes 
correlated between them, a cluster analysis was performed 
considering as statistically significant only the clusters 
with p-values lower than 0.001. In this way four clusters 
with density values ranging from 0.004 to 0.170 were 
selected (Supplementary Figure 7). They comprised639, 
345, 68 and 25 proteins/nodes, respectively, and five HUB 
nodes. In detail, EGFR was in cluster 1, MYC in cluster 
2, ESR1 in cluster 3, and GSTP1 and NQO1 in cluster 4. 
These clusters were named as EGFR cluster, MYC cluster, 
ESR1 cluster and GSTP1-NQO1 cluster, respectively. A 
functional analysis performed on the proteins present in the 
four clusters evidenced that each cluster comprised proteins 
involved in different metabolic pathways in comparison to 
Oncotarget5www.impactjournals.com/oncotarget
those present in the other clusters. In fact, the only common 
pathways between at least two clusters were: i) “cell cycle 
and Epstein-Barr virus infection“ in the case of EGFR and 
MYC clusters, ii) “RNA transport” in the case of ESR1 
and MYC clusters, and iii) “proteoglycans in cancer” in the 
case of EGFR and ESR1 clusters (Supplementary Table 7 
and Supplementary Figure 4).
Overall the cluster analysis demonstrated that our “BC 
and environment” network comprised specific functional 
sub-networks in which some HUB nodes play crucial roles.
Then, to select the sub-network of HUB nodes 
that were more correlated between them and to define 
the related HUB – HUB interaction sub-network, we 
extracted the interactions between HUB nodes in “BC 
and environment” network. In this way, it was possible to 
evidence that: i) four HUB nodes exhibited direct HUB–
HUB interactions in the network (EGFR-IGFBP3 and 
TP53-CDKN1A) and ii) the other HUB nodes were linked 
between them through only one node (Figure 3). This 
finding suggested the strict functional relationship between 
these HUB nodes and how the HUB – HUB sub-network 
could represent a panel of proteins on which we can focus 
further studies in order to verify the possibility to use 
them as specific of the involvement of the environmental 
chemicals in BC initiation.
Moreover, the mutational status of the identified 
HUB nodes was evaluated. This analysis showed that: 
i) eight HUB nodes (ESR1, FAS, GSTM1, IFGBP3, 
KRAS, SOD2 and TNF) did not show mutations in BC, 
ii) CXCL8, NQO1 and MYC had one missense mutation, 
iii) GSTP1 had two missense mutations, iv) CDKN1A 
and EGFR had three missense mutations, v) CDKN2A 
had four missense mutations and vi) TP53 had thirty-eight 
missense mutations (Supplementary Table 8). Moreover, 
the co-occurrence of three mutations, i.e. T384S in EGFR 
and P151H in TP53, D136H in CDKN1A and R273S in 
TP53, and G146V in GSTP1 and G245S in TP53, resulted 
as statistically significant (p-value <0.001) suggesting 
their importance in BC initiation.
Then, to highlight in greater detail the involvement 
of these HUB nodes in BC development, we searched if 
they correlated with clock genes already reported to be 
Figure 3: HUB – HUB interaction sub-network in “BC and environment” network. In details, HUB nodes are reported in 
red whereas the other nodes in cyan.
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altered in BC [9], and if they can be target of miRNAs 
reported to be implicated in BC [38].
In general, the circadian clock system comprises both 
negative and positive regulators, based on an auto-regulatory 
transcriptional and translational feedback program. In this 
context, PER and CRY proteins bind to the promoter region 
of BMAL1 and CLOCK, that are two transcription factors, 
and are capable to reduce the transcription of many genes 
during ambient light exposure [9]. In particular, the basic 
helix-loop-helix (bHLH)/PAS domain transcription factor 
plays a crucial role in the controlling the biological clock 
that controls the circadian rhythms.
Also the urinary system is regulated from the 
circadian rhythms. In fact, during day and night both 
urine excretion and extrusion are actively regulated by 
several internal factors and hormones. Such circadian 
variations led us to postulate that similar to other organs, 
the perturbation of the clockwork may contribute to the 
dysregulation that develops during BC development [9]. 
Since clock genes are able to modify the gene regulation, 
they may interact with the transcription of oncogenes 
and/or tumour suppressor-genes. In fact, a recent paper 
reported the close correlation between altered expression 
of various clock genes and common tumor markers in BC 
evidencing how a disturbed function in the cellular clock 
may be an important additional mechanism contributing to 
cancer progression [9]. Hence, we searched if there were 
correlations between the proteins codified from circadian 
genes (PER1, PER2, PER3, CRY1, CRY2, BMAL1, 
CLOCK, ANTI-CSNK1α1L, CSNK1α and CSNK1ε) and 
our HUB nodes. As visible in Supplementary Figure 5, 
there was a direct correlation between TP53 (HUB node) 
and CSNK1ε (circadian node) and other circadian nodes 
correlated with the other HUB nodes through one or two 
nodes. This demonstrated the strict relationship between 
circadian rhythms and HUB nodes and confirmed how our 
HUB nodes can have an important role in BC development 
in according to the other previous analysis.
The list of the miRNAs implicated in BC by 
microarray studies and verified experimentally by RT-PCR, 
and the list of the genes targeted from these miRNAs was 
extracted by mirNET database (Supplementary Table 9) [38]. 
In this way, it was possible to select only the miRNAs able 
to target our HUB nodes. In detail, our analysis evidenced 
that thirteen miRNAs (hsa-mir-7-5p, hsa-mir-17-5p, hsa-
mir-26a-5p, hsa-mir-30a-3p, hsa-mir-30c-5p, hsa-mir-30e-
5p, hsa-mir-101-3p, hsa-mir-125b-5p, hsa-mir-133b, hsa-
mir-199a-3p, hsa-mir-520b, hsa-mir-639 and hsa-mir-644a) 
correlated with seven HUB nodes (EGFR, SOD2, MYC, 
KRAS, ESR1, CDKN1A and TP53) (Figure 4).
Figure 4: Correlation between HUB – HUB interaction sub-network in “BC and environment” network and miRNAs 
reported as implicated in BC in literature. In details, HUB nodes are reported in red, miRNAs in green and other nodes in cyan.
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In addition, starting from these data, to understand 
if our HUB nodes can have a clinical validity and utility, 
we decided to perform a set of bioinformatics analyses 
on available gene expression datasets BC (TCGA-BLCA). 
The purpose was to assess if there was an association 
between the expression in BC of our HUB nodes and 
patients survival. Our analysis evidenced that high 
expression of EGFR, TP53, MYC, GSTP1, NQO1 and 
KRAS as well as the association of high co-expression of 
TP53-EGFR, MYC-EGFR, KRAS-EGFR, NQO1-EGFR, 
TP53-MYC had a negative effect on the survival (Table 1 
and Supplementary Figure 6).
Identification and analysis of HUB nodes in 
“BC and arsenicals” network
Since BC incidence is very high in the Campania 
region in Italy [3] and the SEBIOREC study demonstrated 
an higher level of arsenic in the serum of subjects living 
in the province of Napoli compared to national average 
[16], a particular attention was directed to establish an 
interaction between arsenicals and fifty-one proteins 
known to be modulated by them (Figure 2). In this study 
we followed the same protocol used in the case of “BC 
and environment” network (Figure 1). As reported in the 
first Results paragraph, the functional analysis on these 
proteins evidenced that they were involved in a set of 
molecular pathways (Supplementary Table 3). These 
fifty-one proteins were mapped on the human molecular 
interactome and the related interaction network named 
“BC and arsenicals” network was extracted and analyzed 
by different topological properties, as reported above 
for the “BC and environment” interaction network 
(Supplementary Figure 7) [24].
This network comprised 353 nodes (proteins) 
and 378 interactions (edges), and the following nine 
HUB nodes: PSMB2, TNF, BIRC3, FANCA, KRAS, 
CCNE1, ERCC4, PABPC1, and PRSS3. It is important 
to evidence that two HUB nodes, TNF and KRAS, were 
in common with the “BC and environment” interaction 
network whereas the others are uniquely regulated by 
arsenicals. Notably, all the HUB nodes, at exception 
of BIRC3 and FANCA, were already resulted to be 
up-regulated in BC by microarray studies [25-31, 39-
43], and be involved in specific molecular functions 
(Supplementary Table 10). However, among the proteins 
already studied in BC, PSMB2 is a very interesting node; 
in fact, it is hypermethylated in BC and was identified as 
indicator of adverse health effects associated with arsenic 
exposure [44]. On the other hand, very few information is 
reported about BIRC3 and FANCA in BC. In particular, 
BIRC3 inhibits apoptosis by binding to tumor necrosis 
factor receptor-associated factors, and is dysregulated in 
some cancers, and FANCA is a DNA repair protein that 
Table 1: Overall survival related to high expression/high co-expression of HUB nodes in the “BC and environment” 
and “BC and arsenicals” networks by SynTarget online tool using public TCGA_BLCA dataset (Bladder Urothelial 
Carcinoma).31 The p-values lower than 0.05 were considered as statistically significant
Nodes Suvival Effect p-value
BC and environment network   
 EGFR negative 0.00124
 TP53 negative 0.00898
 MYC negative 0.0276
 GSTP1 negative 0.0478
 NQO1 negative 0.0379
 KRAS negative 0.017
 TP53-EGFR negative 0.000301
 MYC-EGFR negative 5.23e-06
 KRAS-EGFR negative 0.000591
 NQO1-EGFR negative 0.000134
 TP53-MYC negative 0.00835
BC and arsenicals network   
 KRAS negative 0.017
 ERCC4 negative 0.00424
 ERCC4-KRAS negative 0.0385
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may operate in a post-replication repair or a cell cycle 
checkpoint function. Notably, it could be interesting to 
study in future how these two proteins can be affected 
by arsenicals and through what mechanisms they can be 
involved in BC carcinogenesis.
A detailed analysis of the obtained network showed 
that it had a good centralization equal to 0.402 and a 
network density value of 0.006. The characteristic path 
length of 3.752 confirmed that also this network followed 
the small-world rule [32] as we evidenced for “BC and 
environment” network. Moreover, we can underline 
also that: i) the decreasing trend of the node degree 
distribution plot indicated that our network had scale free 
property with the occurrences of modules (Supplementary 
Figure 8A) [26–29], ii) the decreasing trend of the 
clustering coefficient graph showed the tendency of our 
network to contain HUB nodes (Supplementary Figure 
8B) [43], and iii) the increasing trend of the betweenness 
centrality demonstrated the presence of a HUB node with 
maximum load like PABPC1 (Polyadenylate-Binding 
Protein 1) that is involved in cytoplasmic regulatory 
processes of mRNA metabolism such as pre-mRNA 
(Supplementary Figure 8C).
Then, to study if in the “BC and arsenicals” network 
there were modules characterized by groups of nodes 
correlated between them, a cluster analysis was performed 
as in the case of “BC and environment” network. This 
showed the presence of two clusters (with significant 
P-values lower than 0.005) comprising 15 and 10 proteins/
nodes with density values ranging from 0.608 to 0.644 
and three HUB nodes (Supplementary Figure 9). In detail, 
CCNE1 was in cluster 1 whereas TNF and BIRC3 were in 
cluster 2. However, cluster 1 comprised also CDKN1A, a 
HUB node related to “BC and environmental” network. 
The proteins present in cluster 1 resulted to be involved in 
specific metabolic pathways such as PI3K-Akt signaling 
pathway, p53 signaling pathway and cell cycle, whereas 
those in cluster 2 in Apoptosis, NF-kappa B signaling 
pathway, TNF signaling pathway and Adipocytokine 
signaling pathway. However, the only common 
pathway between two clusters is “Pathways in cancer“ 
(Supplementary Table 11 and Supplementary Figure 10).
As in the case of “BC and environment” network, 
cluster analysis highlighted that the “BC and arsenicals” 
network comprised two sub-networks in which the 
identified HUB nodes played important functional roles.
Moreover, to select the HUB – HUB interaction 
sub-network in “BC and arsenicals” network, we focused 
on the interactions between HUB nodes, and evidenced 
that two HUB nodes (TNF-BIRC3) exhibited direct 
HUB–HUB interactions in network whereas the other 
HUB nodes were linked among them through one or two 
nodes (Figure 5). Moreover, three HUB nodes identified 
for the arsenicals (ERCC4, PABPC1 and CCNE1) resulted 
to interact directly with three HUB nodes evidenced in 
the “BC and environment” network (ERCC4-EGFR, 
PABPC1-ESR1, and CCNE1-CDKN1A) suggesting the 
strict correlation between “BC and arsenicals” and “BC 
and environment” networks.
However the analysis of HUB-HUB interaction sub-
network in “BC and arsenicals” network evidenced how, 
with the exception of TNF and KRAS being in common 
between two networks, the remaining seven HUB nodes 
(PSMB2, BIRC3, FANCA, CCNE1, ERCC4, PABPC1, 
and PRSS3) can be considered as specific of the arsenicals 
involvement in BC development.
The analysis of the mutational status of all the HUB 
nodes, showed that: i) six HUB nodes (CCNE1, KRAS, 
PABPC1, PRSS3, PSMB2 and TNF) had not mutations in 
BC, ii) BIRC3, ERCC4 and FANCA had one, two and four 
missense mutations, respectively (Supplementary Table 
12). No co-occurrence mutations resulted statistically 
significant.
Also in the case of “BC and arsenicals network”, 
we evaluated if there was a correlation between our HUB 
nodes and the clock genes resulted to be altered in BC 
[9]. As visible in Supplementary Figure 11, there was 
no direct correlation between HUB nodes and circadian 
nodes but the circadian nodes correlated with the HUB 
nodes through one or two nodes. This suggested that the 
relationship between circadian rhythms and HUB nodes in 
“BC and arsenicals” network was weaker in comparison 
to what observed for the “BC and environment” network.
Then, we evaluated if our HUB nodes can be targets 
of miRNAs, resulted already as implicated in BC using 
the same protocol reported above. This analysis evidenced 
that seven miRNAs (hsa-mir-7-5p, hsa-mir-17-5p, hsa-
mir-26a-5p, hsa-mir-30a-3p, hsa-mir-125b-5p, hsa-mir-
520b and hsa-mir-646) correlated with four HUB nodes 
(FANCA, CCNE1, KRAS and PABPC1) (Figure 6 and 
Supplementary Table 13).
Among these miRNAs, only hsa-mir-646 did not 
correlate with the HUB nodes of “BC and environmental” 
network. Hence, it could be specific of the involvement of 
arsenicals in BC development.
Finally, we evaluated if there was an association 
between the expression of our HUB nodes in BC and 
patients survival as in the case of “BC and environmental” 
network. Our analysis showed that only the high 
expression of ERCC4 and KRAS and their high co-
expression (ERCC4-KRAS) resulted to have a negative 
effect on the survival in BC patients (Supplementary 
Figure 12 and Table 1).
CONCLUSIONS
No many papers were already published about 
the direct linking between the environmental or arsenic 
exposure and the related modulated proteins in BC. For 
example, it has been shown that arsenic exposure is 
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positively associated with PRSS3 promoter methylation 
levels in BC [45] whereas the effect of NQO1 Pro187Ser 
polymorphism resulted to be more important in never 
smokers because no consistent results were obtained 
about tobacco-related BC risk [46]. Therefore, aim of this 
work was to highlight the correlation between genes and 
proteins that are modulated by environmental exposure 
or only by the arsenicals by network approaches, and to 
identify the related HUB nodes that can be considered as 
specific of the BC development due to environmental or 
arsenicals exposure, and on which can be useful to focus 
further experimental studies in order to verify their utility 
as new diagnostic and/or prognostic biomarkers or targets.
In summary, in our study we reported the creation 
of two networks named as “BC and environment” and 
“BC and arsenicals”, defined a set of HUB nodes and the 
related HUB-HUB interactions, and evidenced that these 
HUB nodes showed significant mutations implicated in BC 
and correlated with genes involved in circadian rhythms. 
In addition, we identified: i) a sub-network of interactions 
between miRNAs and genes that is specific of the correlation 
between BC and environment or arsenicals, and ii) the genes 
correlated to negative effect on the survival in BC patients.
On the basis of our results, we can underline that 
many identified HUB nodes in “BC and environment” and 
“BC and arsenicals” networks are proteins already known 
as to be involved in molecular pathways correlated to the 
development of cancer and BC. However, we evidenced 
also the presence of other proteins for which molecular 
interactions in BC were unknown. For example in “BC 
and environment” network we found the estrogen receptor, 
ESR1, that can be object of further investigations because 
some environmental chemicals are endocrine disruptors 
that can mimic its structure. Hence, this finding can cause 
problems in the endocrine system and could represent 
an initiation point for BC. Moreover, in the case of “BC 
and arsenicals” network, we identified two HUB nodes, 
BIRC3 and FANCA for which the role in BC is unknown. 
Therefore, it can be useful to study if and how these two 
proteins can be affected by arsenicals and if there are specific 
mechanisms through which they can contribute to BC 
carcinogenesis. Certainly these hypothesis may be verified 
Figure 5: HUB – HUB interaction sub-network in “BC and arsenicals” network. In details, HUB nodes are reported in red, 
HUB nodes that were present also in “BC and environmental network” in green and the other nodes in cyan.
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by experimental studies but could represent starting points 
for the identification of new markers for BC.
Finally, it is important to underline that all 
our data fall within the SPES project (http://spes.
campaniatrasparente.it/), in which our group is 
involved, that is an exposure study in susceptible 
population. Its aim is to evaluate the effects on human 
health of different sources of contamination. Through 
the analysis of the spatial distribution of the sources 
of contamination and the concentration values of 
exposure, genetic susceptibility, immune and oxidative 
biomarkers in biological fluids of youth living groups 
in the “Land of Fires” municipalities, it will be possible 
to identify areas that have the same potential index 
of risk. Therefore, the SPES project is collecting sera 
from healthy donors/patients of susceptible population 
to contamination, and, hence, the network studies in 
this work can provide knowledge useful for further 
hypothesis-driven experimental studies and targets 
discovery in BC. In fact, the identification of chemicals-
regulated proteins could help to search for specific 
markers in selected populations. Therefore, considering 
the results of this study, we could think to evaluate: i) 
the expression of TP53 and EGFR, and their mutations 
(T384S of EGFR and P151H of TP53) in sera of 
susceptible individuals to the environmental chemicals 
exposure to verify if they can be used as markers for 
BC and ii) the expression of ERCC4, KRAS and of 
hsa-mir-646 in individuals exposed to contamination of 
drinking water with arsenicals to understand if and what 
among these three molecules can be used as markers for 
BC initiation.
Figure 6: Correlation between HUB – HUB interaction network in “BC and arsenicals” network and miRNAs. In 
details, HUB nodes are reported in red, miRNAs in green, HUB nodes present in “BC and environment” in brown and other nodes in cyan.
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MATERIALS AND METHODS
Network analysis
Comparative Toxicogenomics Database (CTD) 
was used to extract the list of environmental chemicals 
implicated in BC and the related chemical–protein 
interactions [22]. Through the Cytoscape software 
platform for the visualization of complex networks and 
their integration (http://www.cytoscape.org/), a network 
related to the interactions between the proteins modulated 
by the selected environmental chemicals was constructed 
using as reference the human molecular interactome 
(INTACT) [23] where all interactions are derived from 
literature curation or direct user submissions and are 
freely available. Some statistical analyses were performed 
the following three measures of centrality: i) the degree 
that indicates the number of interactions of a particular 
node with other nodes in the network; ii) the betweenness 
centrality that evaluates the importance of a node in the 
network and how the other interactions in the network 
are controlled by this node [47]; and iii) the closeness 
centrality of a node that is calculated as the sum of the 
length of the shortest paths between the node and all 
other nodes in the graph and ranges from 0 to 1 [48]. 
Then, we evaluated also other topological analyses like 
average characteristic path length, network density, and 
centralization [48–50]. The characteristic path length is 
calculated by finding the shortest path between all pairs 
of nodes, adding them up, and then dividing by the total 
number of pairs. This indicates the number of steps that 
takes to get from one member of the network to another. 
The density of a network is defined as a ratio of the 
number of edges to the number of possible edges [48] 
whereas the centralization produces rankings, which seek 
to identify the most important nodes in a network model 
ranging from 1 to 0 [49].
Finally, we performed a cluster analysis by means 
of Cluster-One [50] that is the task of grouping a set 
of objects in such a way that objects in the same group 
(called a cluster) are more similar to each other than to 
those in other groups (clusters) [51].
Functional and Pathway Analyses were performed 
by DAVID program [52].
miRNA evaluations
The miRNAs able to target the HUB nodes were 
selected by MirNet tool [53]. In details, we performed the 
following protocol: firstly, we extracted the list of miRNAs 
involved in BC; secondly, starting from this miRNA list 
we extracted all their targets; finally we selected only the 
miRNAs that targeted our HUB nodes. Then, using the list 
of our HUB nodes and the related miRNAs, an interaction 
network between selected miRNAs and HUB nodes was 
constructed by the Cytoscape package.
Survival gene effect analysis
Bionformatic analyses were performed by SynTarget 
online tool able to test the synergetic effect of genes on 
survival outcome in cancer (http://www.bioprofiling.de) 
using public TCGA_BLCA dataset (Bladder Urothelial 
Carcinoma) [53]. In details, PPISURV tool was used 
to test if our genes can be used as biomarker of cancer 
survival.
Gene mutation analysis
Mutation analysis was conducted by cBioPortal for 
Cancer Genomics tool able to analyze cancer genomics 
data in order to test the presence of mutations on genes 
involved in cancer (http://cbioportal.org) [54–55].
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